Edico Genome Uses Amazon Web Services to Achieve Real-Time Genomic Analysis, Provide Scalable and Secure Cloud-Based Platform

SAN DIEGO, Nov. 30, 2016 /PRNewswire/ — Edico Genome, creator of the world’s first bio-IT processor designed to analyze next-generation sequencing data, today announced that they are deploying DRAGEN on AWS’ newly available Amazon EC2 F1 instances, which are Field Programmable Gate Array (FPGA)-enabled instances in the cloud, potentially reducing analysis times from 26 minutes for a whole genome to real time.

“DRAGEN customers appreciate that Edico continues to break new ground to make genomic analysis as rapid as technology allows. With AWS’ newest FPGA-based instances, DRAGEN will be able to analyze whole genomes in almost real time, which is unprecedented and would be a world first,” said Pieter van Rooyen, Ph.D., chief executive officer of Edico Genome. “We look forward to offering a secure, highly scalable, and cost-efficient platform for genomic analysis to Edico customers, hospitals, academic institutions, drug developers, sequencing centers and others advancing genomic-based work.” 

A cloud configuration provides users with the flexibility to scale up to the cloud during times of high capacity and return to onsite analysis when demand is reduced. The platform is compliant with the Health Insurance Portability and Accountability Act, regulations developed by the U.S. Department of Health and Human Services to protect the privacy and security of patients’ health information. Onsite analysis is also feasible, with both systems managed through the DRAGEN web portal, featuring an easy-to-use graphical user interface. Pipelines are identical whether executed in the cloud or onsite.

DRAGEN is highly reconfigurable, using FPGA to provide hardware-accelerated implementations of genome pipeline algorithms, such as BCL conversion, compression, mapping, alignment, sorting, duplicate marking, and haplotype variant calling. The flexible DRAGEN platform allows Edico to develop custom algorithms as well as refine and improve existing pipelines. The following end-to-end, clinical-grade pipelines are currently available on the DRAGEN platform: genome/exome, transcriptome/RNA-seq, epigenome/methyl-seq, metagenome/microbiome, joint genotyping and GATK 3.6. Updated versions are made available for customers through regular, simple remote downloads. 

Pricing for the DRAGEN cloud solution on AWS will be announced by year end.

About Edico Genome
Edico Genome has created the world’s first bioinformatics processor designed to analyze next-generation sequencing data, DRAGEN™. The use of next-generation sequencing is growing at an unprecedented pace, creating a need for a technology that can process this big data rapidly and accurately. Edico Genome’s computing platform has been shown to speed whole genome data analysis from hours to minutes, while maintaining high accuracy and reducing costs, enabling clinicians and researchers to reveal answers more quickly. For more information, visit www.EdicoGenome.com or follow @EdicoGenome.